|Bid||43.15 x 900|
|Ask||44.75 x 3200|
|Day's Range||43.51 - 44.71|
|52 Week Range||39.07 - 65.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.91|
We are closing in on the end of another week in the biotechnology space just as was the case last week, we’ve seen plenty of movement in the sector on the back of a number of fresh releases. Here is a look at the most pertinent and a description of what it means for the […] The post Akcea and Ionis Just Got A Major Boost appeared first on Market Exclusive.
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS) today announced that the U.S. Food and Drug Administration’s (FDA) Division of Metabolism and Endocrinology Products Advisory Committee voted 12-8 to support approval of WAYLIVRATM (volanesorsen) for the treatment of people with familial chylomicronemia syndrome (FCS). The committee’s non-binding recommendation will be considered by the FDA in its review of Akcea’s New Drug Application for WAYLIVRA. The PDUFA date for completion of the review of WAYLIVRA is August 30, 2018. “We look forward to working with the FDA to complete the final stages of regulatory review for WAYLIVRA.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
The following are a few things for investors to know about Ionis Pharmaceuticals Inc’s most recent earnings report. This is down from its earnings per share of 7 cents reported in the same period of the year prior. Ionis Pharmaceuticals Inc also reported a net loss of $10.81 million for the first quarter of 2018.
Ionis Pharmaceuticals Inc. shares rose 3.9% in premarket trade Friday after the company reported first-quarter profit and revenue beats. The company reported a loss of $1.42 million, or a loss of 1 cent per share, after earnings of $8.96 million, or 7 cents per share, in the year-earlier period. Ionis said it and Biogen expect their recent deal to close in the second quarter.
On a per-share basis, the Carlsbad, California-based company said it had a loss of 1 cent. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Total revenues increased by 25%, driven by SPINRAZA royalties More than $2 billion of cash expected upon closing of Biogen transaction Expanded strategic neurology research collaboration with Biogen and ...
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
CAMBRIDGE, Mass. and LAS VEGAS, April 26, 2018-- Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat people with serious and ...
CAMBRIDGE, Mass., April 26, 2018-- Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Thursday, May 3 rd at 4:30 p.m. Eastern Time ...
The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
On April 20, Biogen (BIIB) and Ionis Pharmaceuticals (IONS) announced the expansion of their strategic collaboration to develop drug candidates targeted at a range of neurological diseases. This key move builds on the productive collaboration between the two companies that led to the development of Spinraza, the first and only approved treatment for patients with spinal muscular atrophy, along with two antisense drug candidates that are currently under development.
In 1Q18, Biogen’s (BIIB) Spinraza generated revenues of $364 million compared to $47 million in 1Q17 and $363 million in 4Q17. In 1Q18 in the US and international markets, Spinraza generated revenues of $188 million and $176 million, respectively, compared to $46 million and $1 million, respectively, in 1Q17. Spinraza is used in the treatment of individuals with spinal muscular atrophy.
Results from exploratory analyses of data from the study demonstrated correlations between reductions in mutant huntingtin (mHTT), the disease-causing protein, and improvements in clinical measures of Huntington's disease.